Evidence map›Paper›PMID 35436221›Full record

SynthesisJournal of medical Internet research2022

Recommendations for Defining and Reporting Adherence Measured by Biometric Monitoring Technologies: Systematic Review.

Iredia M Olaye, Mia P Belovsky, Lauren Bataille, Royce Cheng, Ali Ciger, Karen L Fortuna, Elena S Izmailova, Debbe McCall, Christopher J Miller, Willie Muehlhausen and 6 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Journal of medical Internet research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 4 countries.

Iredia M OlayeDepartment of Medicine Division of Clinical Epidemiology and Evaluative Sciences Research, Weill Cornell Medical College Cornell University, New York, NY, United States.ORCID 0000-0002-3888-0854
Mia P BelovskySidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, United States.ORCID 0000-0002-2822-9013
Lauren BatailleNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.ORCID 0000-0001-6825-6000
Royce ChengHealth Platforms, Verily Life Sciences, Cambridge, MA, United States.ORCID 0000-0002-5962-8666
Ali CigerPfizer, Berlin, Germany.ORCID 0000-0003-3311-1850
Karen L FortunaGiesel School of Medicine at Dartmouth College, Hanover, NH, United States.ORCID 0000-0003-0343-2346
Elena S IzmailovaKoneksa Health, New York, NY, United States.ORCID 0000-0002-7150-1748
Christopher J MillerAstraZeneca Pharmaceuticals LP, Gaithersburg, MD, United States.ORCID 0000-0002-9944-4204
Willie MuehlhausenSAFIRA Clinical Research, Cloughjordan, Ireland.ORCID 0000-0001-9198-1622
Carrie A NorthcottPfizer Inc, Cambridge, MA, United States.ORCID 0000-0002-0197-4144
Isaac R Rodriguez-ChavezICON plc, Blue Bell, PA, United States.ORCID 0000-0003-1787-8381
Abhishek PratapCAMH Krembil Center for Neuroinformatics, Toronto, ON, Canada.ORCID 0000-0002-5289-6932
Benjamin VandendriesscheByteflies, Antwerp, Belgium.ORCID 0000-0003-0672-0327
Yaara Zisman-IlaniDepartment of Social and Behavioral Sciences; College of Public Health, Temple University, Philadelphia, PA, United States.ORCID 0000-0001-6852-2583
Jessie P BakkerSignifier Medical Technologies, Needham, MA, United States.ORCID 0000-0002-2976-4747
AstraZeneca (United States) · USCase Western Reserve University · USCornell University · USDartmouth College · USKing's College London · GBNovartis (United States) · USPfizer (Germany) · DEPfizer (United States) · USTemple University · USThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSuboptimal adherence to data collection procedures or a study intervention is often the cause of a failed clinical trial. Data from connected sensors, including wearables, referred to here as biometric monitoring technologies (BioMeTs), are capable of capturing adherence to both digital therapeutics and digital data collection procedures, thereby providing the opportunity to identify the determinants of adherence and thereafter, methods to maximize adherence.

objectiveWe aim to describe the methods and definitions by which adherence has been captured and reported using BioMeTs in recent years. Identifying key gaps allowed us to make recommendations regarding minimum reporting requirements and consistency of definitions for BioMeT-based adherence data.

methodsWe conducted a systematic review of studies published between 2014 and 2019, which deployed a BioMeT outside the clinical or laboratory setting for which a quantitative, nonsurrogate, sensor-based measurement of adherence was reported. After systematically screening the manuscripts for eligibility, we extracted details regarding study design, participants, the BioMeT or BioMeTs used, and the definition and units of adherence. The primary definitions of adherence were categorized as a continuous variable based on duration (highest resolution), a continuous variable based on the number of measurements completed, or a categorical variable (lowest resolution).

resultsOur PubMed search terms identified 940 manuscripts; 100 (10.6%) met our eligibility criteria and contained descriptions of 110 BioMeTs. During literature screening, we found that 30% (53/177) of the studies that used a BioMeT outside of the clinical or laboratory setting failed to report a sensor-based, nonsurrogate, quantitative measurement of adherence. We identified 37 unique definitions of adherence reported for the 110 BioMeTs and observed that uniformity of adherence definitions was associated with the resolution of the data reported. When adherence was reported as a continuous time-based variable, the same definition of adherence was adopted for 92% (46/50) of the tools. However, when adherence data were simplified to a categorical variable, we observed 25 unique definitions of adherence reported for 37 tools.

conclusionsWe recommend that quantitative, nonsurrogate, sensor-based adherence data be reported for all BioMeTs when feasible; a clear description of the sensor or sensors used to capture adherence data, the algorithm or algorithms that convert sample-level measurements to a metric of adherence, and the analytic validation data demonstrating that BioMeT-generated adherence is an accurate and reliable measurement of actual use be provided when available; and primary adherence data be reported as a continuous variable followed by categorical definitions if needed, and that the categories adopted are supported by clinical validation data and/or consistent with previous reports.

Indexed as

BiometryCimetidineData CollectionHumansResearch DesignTechnologyCimetidineadherencecompliancedigital measuresdigital medicinemobile phone

Identifiers

PMID35436221
PMCPMC9052021
OpenAlexW4224263780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.